PriceTargets.com logo

Telix Pharmaceuticals Limited American Depositary Shares - TLX Stock Price Target and Predictions

  • Consensus Rating: Strong Buy
  • Consensus Price Target: $22.00
  • Forecasted Upside: 22.77%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 1 Strong Buy Ratings
$17.92 As of 01/27/2025 04:58 PM ET
▼ -0.32 (-1.75%)

This chart shows the closing price for TLX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Telix Pharmaceuticals Limited American Depositary Shares Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TLX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TLX

Analyst Price Target is $22.00
▲ +22.77% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Telix Pharmaceuticals Limited American Depositary Shares in the last 3 months. The average price target is $22.00, with a high forecast of $22.00 and a low forecast of $22.00. The average price target represents a 22.77% upside from the last price of $17.92.

This chart shows the closing price for TLX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Strong Buy

The current consensus among 2 contributing investment analysts is to buy (strong buy) stock in Telix Pharmaceuticals Limited American Depositary Shares.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/28/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2025

Latest Recommendations

  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/27/2025UBS GroupBoost TargetBuy ➝ Buy$21.00 ➝ $22.00
11/19/2024William BlairUpgradeStrong-Buy
11/15/2024UBS GroupInitiated CoverageBuy$21.00
(Data available from 1/27/2020 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/1/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/31/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/30/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2024
  • 4 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
1/27/2025

Current Sentiment

  • 4 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Telix Pharmaceuticals Limited American Depositary Shares logo
Telix Pharmaceuticals Limited is a biopharmaceutical company which focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It involved in developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix Pharmaceuticals Limited is headquartered in Melbourne, Australia.
Read More

Today's Range

Now: $17.92
Low: $17.90
High: $19.20

50 Day Range

MA: $15.81
Low: $14.56
High: $18.24

52 Week Range

Now: $17.92
Low: $14.01
High: $19.99

Volume

24,718 shs

Average Volume

13,164 shs

Market Capitalization

$6.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Telix Pharmaceuticals Limited American Depositary Shares?

The following Wall Street research analysts have issued research reports on Telix Pharmaceuticals Limited American Depositary Shares in the last twelve months: UBS Group AG, and William Blair.
View the latest analyst ratings for TLX.

What is the current price target for Telix Pharmaceuticals Limited American Depositary Shares?

0 Wall Street analysts have set twelve-month price targets for Telix Pharmaceuticals Limited American Depositary Shares in the last year. Their average twelve-month price target is $22.00, suggesting a possible upside of 22.8%. UBS Group AG has the highest price target set, predicting TLX will reach $22.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $22.00 for Telix Pharmaceuticals Limited American Depositary Shares in the next year.
View the latest price targets for TLX.

What is the current consensus analyst rating for Telix Pharmaceuticals Limited American Depositary Shares?

Telix Pharmaceuticals Limited American Depositary Shares currently has 1 buy rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Strong Buy."
View the latest ratings for TLX.

What other companies compete with Telix Pharmaceuticals Limited American Depositary Shares?

Other companies that are similar to Telix Pharmaceuticals Limited American Depositary Shares include Royalty Pharma, BeiGene, Summit Therapeutics, United Therapeutics and Insmed. Learn More about companies similar to Telix Pharmaceuticals Limited American Depositary Shares.

How do I contact Telix Pharmaceuticals Limited American Depositary Shares' investor relations team?

The company's listed phone number is 61-3-9093-3855 and its investor relations email address is [email protected]. The official website for Telix Pharmaceuticals Limited American Depositary Shares is www.telixpharma.com. Learn More about contacing Telix Pharmaceuticals Limited American Depositary Shares investor relations.